severe covid-19 disease: defined as presence of spo₂ less than 93% on room air or a pao₂ to fio₂ ratio of 300 or lower. patients on ventilatory support. cardiac dysfunction that would preclude treatment with hydroxychloroquine: patients on medication known to prolong qt segment. known history of lqt syndrome. acquired qt prolongation at baseline >500ms. av block. bundle branch block. known history of cardiomyopathy, pulmonary hypertension, or sick sinus syndrome. history of ventricular tachyarrhythmia. patients with implantable cardioverter-defibrillator (icd). patients with a baseline bradycardia of less than 50 beats per minute. renal dysfunction (estimated glomerular filtration rate less than 30ml/min). hepatic dysfunction defined as: transaminitis more than three times the upper limit of normal or chronic liver disease of child pugh class b or higher. gout or a history of gout patients that are pregnant or breastfeeding. patients with a known allergy to an intervention medication. patients who receive any of the study medications prior to randomization patient with g6pd readmission due to covid19 disease. participants in any other covid-19 disease trial. patients on immunosuppressants, hiv patients, cancer patients who received chemotherapy within the past 6 months, or who are on chronic oral steroids. patients unable to give informed consent.

severe covid-19 disease: defined as presence of spo₂ less than 93% on room air or a pao₂ to fio₂ ratio of 300 or lower. patients on ventilatory support. cardiac dysfunction that would preclude treatment with hydroxychloroquine: patients on medication known to prolong qt segment. known history of lqt syndrome. acquired qt prolongation at baseline >500ms. av block. bundle branch block. known history of cardiomyopathy, pulmonary hypertension, or sick sinus syndrome. history of ventricular tachyarrhythmia. patients with implantable cardioverter-defibrillator (icd). patients with a baseline bradycardia of less than 50 beats per minute. renal dysfunction (estimated glomerular filtration rate less than 30ml/min). hepatic dysfunction defined as: transaminitis more than three times the upper limit of normal or chronic liver disease of child pugh class b or higher. gout or a history of gout patients that are pregnant or breastfeeding. patients with a known allergy to an intervention medication. patients who receive any of the study medications prior to randomization patient with g6pd readmission due to covid19 disease. participants in any other covid-19 disease trial. patients on immunosuppressants, hiv patients, cancer patients who received chemotherapy within the past 6 months, or who are on chronic oral steroids. patients unable to give informed consent.

- severe covid-19 disease: defined as presence of spo₂ less than 93% on room air or a pao₂ to fio₂ ratio of 300 or lower. - patients on ventilatory support. - cardiac dysfunction that would preclude treatment with hydroxychloroquine: 1. patients on medication known to prolong qt segment. 2. known history of lqt syndrome. 3. acquired qt prolongation at baseline >500ms. 4. av block. 5. bundle branch block. 6. known history of cardiomyopathy, pulmonary hypertension, or sick sinus syndrome. 7. history of ventricular tachyarrhythmia. 8. patients with implantable cardioverter-defibrillator (icd). 9. patients with a baseline bradycardia of less than 50 beats per minute. - renal dysfunction (estimated glomerular filtration rate less than 30ml/min). - hepatic dysfunction defined as: 1. transaminitis more than three times the upper limit of normal or 2. chronic liver disease of child pugh class b or higher. - gout or a history of gout - patients that are pregnant or breastfeeding. - patients with a known allergy to an intervention medication. - patients who receive any of the study medications prior to randomization - patient with g6pd - readmission due to covid19 disease. - participants in any other covid-19 disease trial. - patients on immunosuppressants, hiv patients, cancer patients who received chemotherapy within the past 6 months, or who are on chronic oral steroids. - patients unable to give informed consent.

- severe covid-19 disease: defined as presence of spo₂ less than 93% on room air or a pao₂ to fio₂ ratio of 300 or lower. - patients on ventilatory support. - cardiac dysfunction that would preclude treatment with hydroxychloroquine: 1. patients on medication known to prolong qt segment. 2. known history of lqt syndrome. 3. acquired qt prolongation at baseline >500ms. 4. av block. 5. bundle branch block. 6. known history of cardiomyopathy, pulmonary hypertension, or sick sinus syndrome. 7. history of ventricular tachyarrhythmia. 8. patients with implantable cardioverter-defibrillator (icd). 9. patients with a baseline bradycardia of less than 50 beats per minute. - renal dysfunction (estimated glomerular filtration rate less than 30ml/min). - hepatic dysfunction defined as: 1. transaminitis more than three times the upper limit of normal or 2. chronic liver disease of child pugh class b or higher. - gout or a history of gout - patients that are pregnant or breastfeeding. - patients with a known allergy to an intervention medication. - patients who receive any of the study medications prior to randomization - patient with g6pd - readmission due to covid19 disease. - participants in any other covid-19 disease trial. - patients on immunosuppressants, hiv patients, cancer patients who received chemotherapy within the past 6 months, or who are on chronic oral steroids. - patients unable to give informed consent.

- severe covid-19 disease: defined as presence of spo₂ less than or equal to 93% on room air or a pao₂ to fio₂ ratio of 300 or lower. - patients on ventilatory support. - cardiac dysfunction that would preclude treatment with hydroxychloroquine: 1. patients on medication known to prolong qt segment. 2. known history of lqt syndrome. 3. acquired qt prolongation at baseline >500ms. 4. av block. 5. bundle branch block. 6. known history of cardiomyopathy, pulmonary hypertension, or sick sinus syndrome. 7. history of ventricular tachyarrhythmia. 8. patients with implantable cardioverter-defibrillator (icd). 9. patients with a baseline bradycardia of less than 50 beats per minute. - renal dysfunction (estimated glomerular filtration rate less than 30ml/min). - hepatic dysfunction defined as: 1. transaminitis more than three times the upper limit of normal or 2. chronic liver disease of child pugh class b or higher. - gout or a history of gout - patients that are pregnant or breastfeeding. - patients with a known allergy to an intervention medication. - patients who receive any of the study medications prior to randomization - patient with g6pd - readmission due to covid19 disease. - participants in any other covid-19 disease trial. - patients on immunosuppressants, hiv patients, cancer patients who received chemotherapy within the past 6 months, or who are on chronic oral steroids. - patients unable to give informed consent.

- severe covid-19 disease: defined as presence of spo₂ less than or equal to 93% on room air or a pao₂ to fio₂ ratio of 300 or lower. - patients on ventilatory support. - cardiac dysfunction that would preclude treatment with hydroxychloroquine: 1. patients on medication known to prolong qt segment. 2. known history of lqt syndrome. 3. acquired qt prolongation at baseline >500ms. 4. av block. 5. bundle branch block. 6. known history of cardiomyopathy, pulmonary hypertension, or sick sinus syndrome. 7. history of ventricular tachyarrhythmia. 8. patients with implantable cardioverter-defibrillator (icd). 9. patients with a baseline bradycardia of less than 50 beats per minute. - renal dysfunction (estimated glomerular filtration rate less than 30ml/min). - hepatic dysfunction defined as: 1. transaminitis more than three times the upper limit of normal or 2. chronic liver disease of child pugh class b or higher. - gout or a history of gout - patients that are pregnant or breastfeeding. - patients with a known allergy to an intervention medication. - patients who receive any of the study medications prior to randomization - patient with g6pd - readmission due to covid19 disease. - participants in any other covid-19 disease trial. - patients on immunosuppressants, hiv patients, cancer patients who received chemotherapy within the past 6 months, or who are on chronic oral steroids. - patients unable to give informed consent.